Claims for Patent: RE43916
✉ Email this page to a colleague
Summary for Patent: RE43916
| Title: | Composition for contraception |
| Abstract: | A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days. |
| Inventor(s): | Spona; Jurgen (Vienna, AT), Dusterberg; Bernd (Berlin, DE), Ludicke; Frank (Basel, CH) |
| Assignee: | Bayer Schering Pharma Aktiengesellschaft (Berlin, DE) |
| Application Number: | 11/388,172 |
| Patent Claims: |
1. A combination product for oral contraception, comprising (a) 23 or 24 dosage units, each containing an estrogen selected from >2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg
of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, and b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of
the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days..].
.[.2. A combination preparation for oral contraception according to claim 1, wherein the estrogen is ethinylestradiol..]. .[.3. A combination preparation of claim 2, wherein the gestagen is cyproterone acetate..]. .[.4. A combination preparation of claim 2, wherein the gestagen is drospirenone..]. .[.5. A combination preparation according to claim 1, wherein the estrogen is present in a dose of 20 .mu.g of ethinylestradiol or an equivalent dose of 17.beta.-estradiol and the gestagen is present in a dose equivalent to 75 .mu.g of gestadene..]. .[.6. A combination preparation according to claim 1, which comprises 23 dosage units and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle..]. .[.7. A combination preparation according to claim 1, which comprises 23 dosage units, each containing 20 .mu.g of ethinylestradiol and a dose of cyproterone acetate or drospirenone equivalent to 75 .mu.g of gestodene and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle..]. .[.8. A combination preparation of claim 1, wherein the estrogen is 17.beta.-estradiol..]. .[.9. A combination preparation of claim 8, wherein the gestagen is cyproterone acetate..]. .[.10. A combination preparation of claim 8, wherein the gestagen is drospirenone..]. .Iadd.11. A method of inducing contraception in a female of reproductive age who has not yet reached premenopause, comprising administering to said female who is desirous of contraception a monophasic composition comprising an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.015 to 0.020 mg of ethynylestradiol; and a contraceptively effective amount of a gestagen, wherein the composition is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle..Iaddend. .Iadd.12. A method of claim 11 wherein the gestagen is norethisterone..Iaddend. .Iadd.13. A method of claim 11 wherein the gestagen is drospirenone..Iaddend. .Iadd.14. A method of claim 13 wherein the amount of drospirenone in said composition is 1-3 mg..Iaddend. .Iadd.15. A method of inducing contraception in a female of reproductive age who has not yet reached premenopause, comprising administering to said female who is desirous of contraception a monophasic composition comprising 0.015 to 0.020 mg of ethynylestradiol and 1-3 mg of drospirenone, wherein the composition is administered for 23 or 24 days, beginning on day one of the menstrual cycle, followed by 5 or 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle..Iaddend. .Iadd.16. A method of claim 15 wherein the amount of ethynylestradiol is 0.020 mg and the amount of drospirenone is 3 mg..Iaddend. .Iadd.17. A method of claim 16 wherein the composition is administered for 24 days, beginning on day one of the menstrual cycle, followed by 4 pill-free or sugar pill days, during a total of 28 days in the administration cycle..Iaddend. |
